Cannabis Therapy Corp. (CTCO) 0.4850 $CTCO
Idrasil Publishes First White Paper On Cannabis Therapy In Over A Decade
PRWeb - Wed Aug 20, 3:02AM CDT
C3 International, Inc., manufacturer of Idrasil™, the first natural cannabis tablet on the market, has published a white paper revisiting the effects of cannabis-based therapy on migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions.
Easton and GW Pharmaceuticals Lead Cannabis Stocks Higher Last Week
ACCESSWIRE - Tue Aug 19, 9:02AM CDT
WHITEFISH, MT / ACCESSWIRE / August 19, 2014 / The Marijuana Index(TM) moved marginally higher last week, driven by a 7.71% rise in GW Pharmaceuticals plc (NASDAQ: GWPH) shares, which was partially offset by a 15.3% drop in Medbox Inc. (OTC: MDBX) shares.
Cannabis Therapy Corp Extends Strategic Plan Into Cannabinoid Products for Animal Health
ACCESSWIRE - Thu Aug 14, 11:48AM CDT
Whitefish, MT / August 14, 2014 / From spending on cardiology to oncology to specialty foods, people love their pets and religiously earmark income for requisite and discretionary spending on their furry friends. This is evident through industry expert American Pet Products stating overall expenditures in the pet industry climbed from $43.2 billion in 2008 to $55.72 billion in 2013. Not even the 2009-2013 Great Recession caused consumers to hit the brakes hard on allocating cash for their pets. The largest chunk of the overall spending went to food ($22.6 billion), followed by the veterinary care category ($15.3 billion) and then supplies/Over-the-Counter medicine ($13.7 billion). As noted by Embrace Pet Insurance, the supplies/OTC meds category remains robust, with their analysts estimating that growth in this sector outpaced the 6.7% expansion forecast by American Pet Products in 2013.
Vape Holdings & Terra Tech Were Top Cannabis Stock Gainers Last Week
ACCESSWIRE - Tue Aug 12, 8:47AM CDT
WHITEFISH, MT / August 12, 2014 / The Marijuana Index(TM) moved lower last week, as bellwethers GW Pharmaceuticals plc (NASDAQ: GWPH) and MedBox Inc. (OTC: MDBX) fell 0.8% and 14%, respectively, alongside many other smaller industry components.
Cannabis Therapy Corp. Moves to Leverage Pet Health Sector and Offers Details on New Product Lineup
Marketwire - Tue Aug 12, 8:03AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"
, a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, ultra-low THC, cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is pleased to offer additional information regarding its Canna-Pet(TM) product mix, and subsequent plans for upcoming marketing activities to support the recently announced worldwide and exclusive licensing of the entire Canna-Pet(TM) brand and animal health operation.
Cannabis Therapy Expands into Animal Health Marketplace
ACCESSWIRE - Wed Aug 06, 8:35AM CDT
WHITEFISH, MT / August 6, 2014 / Consumers will spend an estimated $58.51 billion on their pets in 2014, according to the American Pet Products Association's National Pet Owners Survey, which is up 5% from the $55.72 billion spent last year. Even with the global economic crisis of 2008, the industry has managed to grow every year since 2001, as consumers are willing to spend on their pets even when they can't afford to spend on themselves.
Cannabis Therapy Corp. and Canna-Pet, LLC Enter Exclusive Licensing Agreement
Marketwire - Tue Aug 05, 8:11AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company" , a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, ultra-low THC, cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is very pleased to announce the execution of a definitive licensing agreement with Canna-Pet, LLC of Seattle, WA.
Cannabis Stocks Edge Higher Last Week Led by Nuvilex & Entertopia
ACCESSWIRE - Tue Jul 22, 8:32AM CDT
WHITEFISH, MT / July 22, 2014 / The Marijuana Index(TM) moved slightly higher last week, despite a 7% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares. Medbox Inc. (OTC: MDBX), the second largest component of the index, also fell over 5% last week.
Cannabis Stocks Move Higher as Washington State Pot Sales Begin
ACCESSWIRE - Mon Jul 14, 8:30AM CDT
WHITEFISH, MT / July 14, 2014 / The Marijuana Index(TM) moved higher last week in the aggregate, despite a 13% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares and a roughly 1.5% drop in Medbox Inc. (OTC: MDBX) shares, which comprise about half of the weighted index.
Cannabis Sativa & Easton Pharmaceuticals Led Cannabis Stocks Higher Last Week
ACCESSWIRE - Tue Jul 08, 8:07AM CDT
Whitefish, MT / July 8, 2014 / The Marijuana Index(tm) was mixed last week, as index heavyweights GW Pharmaceuticals plc (NASDAQ: GWPH) and Medbox Inc. (OTC: MDBX) gave up some of their earlier gains towards the end of the week.
Cannabis Therapy Corp. Commences Research to Support Development of New, Hemp-Based, Anti-Inflammatory Products
Marketwire - Tue Jul 08, 8:03AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company" , a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is pleased to advise it is commencing exploratory laboratory research aimed at the development of cannabinoid-based products with potential application specific to inflammatory and auto-immune diseases.
Marijuana Sector Positioned to Move Higher as FDA Reviews Drug's Status
ACCESSWIRE - Mon Jun 30, 8:32AM CDT
WHITEFISH, MT / June 30, 2014 / The Marijuana Index(TM) traded marginally lower last week after MedBox Inc. (OTC: MDBX) and CannaVEST Corp.'s (OTC: CANV) moves lower offset GW Pharmaceuticals plc's (NASDAQ: GWPH) modest gains.
Cannabis Therapy Corp. Views FDA Reclassification Analysis as a Potential Win for Both Industry and Consumers
Marketwire - Mon Jun 30, 8:02AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company" a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is very pleased to note recent media reports that the U.S. Food and Drug Administration ("FDA" , at the request of the Drug Enforcement Administration ("DEA" , is conducting an analysis on whether the U.S. should downgrade the classification of marijuana as a Schedule 1 drug.
Cannabis Therapy Corp. Crop Management Advantage Accelerates Regional Farm Activity
Marketwire - Wed Jun 25, 8:03AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company" a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is pleased to advise that its initial crop of hemp cultivars is well underway with plants exhibiting normal healthy growth characteristics and a current height of approximately 16 inches.
Cannabis Therapy Uses Hemp to Shorten Time to Market
ACCESSWIRE - Mon Jun 23, 9:14AM CDT
WHITEFISH, MT / June 23, 2014 / Medical marijuana remains very controversial despite the favorable regulatory progress made over the past couple of years. While NORML polls suggest 80% of U.S. citizens support medical marijuana legalization, the remaining 20% represent a vocal minority that continue to campaign against it. Perhaps most importantly, the U.S. federal government still considers marijuana to be a Schedule I Controlled Substance.
Cannabis Therapy Pursues IP Strategy in Cannabis Industry
ACCESSWIRE - Wed Jun 18, 8:29AM CDT
Whitefish, MT / June 18, 2014 / Cannabis Therapy Corp (OTC: CTCO) a development stage company that aims to become a leader in the research, development, and commercialization of cannabinoid-based medicinal therapies and supplements, recently announced that it has selected international law firm Nixon Peabody LLP to manage and protect its current and future intellectual property assets.
Cannabis Therapy Corp. Engages Nixon Peabody LLP for IP Protection
Marketwire - Wed Jun 18, 1:27AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company" , a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), has selected international law firm Nixon Peabody LLP to manage and protect its current and future intellectual property assets.
CannabisFN Weekly: Stocks Tread Water amid Regulatory Gains
ACCESSWIRE - Tue Jun 17, 1:00PM CDT
Whitefish, MT / June 17, 2014 / The Marijuana Index(tm) traded roughly even last week, although the sector remains well below its highs achieved earlier this year.
Cannabis Therapy Corp. CEO Conducts In-Depth Video Interview on CFN
Marketwire - Thu Jun 12, 8:02AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company" a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is very pleased to advise that its CEO, Dr. Soren Mogelsvang, recently conducted an in-depth video interview regarding the Company's goals and path to sustainability which is now available for review at http://bit.ly/1lkUK5l.
Cannabis Therapy Corp. Announces Close of Restructuring and Confirms Appointment of Biotech Executive as Director
Marketwire - Wed Apr 02, 8:03AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (formerly OTCQB: FWSI) (the "Company" is pleased to advise it has successfully concluded its previously announced corporate restructuring in connection with its entry into the business of manufacturing and marketing pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of cannabis, for the treatment of various conditions and diseases.
Idrasil Publishes First White Paper On Cannabis Therapy In Over A Decade
PRWeb - Wed Aug 20, 3:02AM CDT
C3 International, Inc., manufacturer of Idrasil™, the first natural cannabis tablet on the market, has published a white paper revisiting the effects of cannabis-based therapy on migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions.
Easton and GW Pharmaceuticals Lead Cannabis Stocks Higher Last Week
ACCESSWIRE - Tue Aug 19, 9:02AM CDT
WHITEFISH, MT / ACCESSWIRE / August 19, 2014 / The Marijuana Index(TM) moved marginally higher last week, driven by a 7.71% rise in GW Pharmaceuticals plc (NASDAQ: GWPH) shares, which was partially offset by a 15.3% drop in Medbox Inc. (OTC: MDBX) shares.
Cannabis Therapy Corp Extends Strategic Plan Into Cannabinoid Products for Animal Health
ACCESSWIRE - Thu Aug 14, 11:48AM CDT
Whitefish, MT / August 14, 2014 / From spending on cardiology to oncology to specialty foods, people love their pets and religiously earmark income for requisite and discretionary spending on their furry friends. This is evident through industry expert American Pet Products stating overall expenditures in the pet industry climbed from $43.2 billion in 2008 to $55.72 billion in 2013. Not even the 2009-2013 Great Recession caused consumers to hit the brakes hard on allocating cash for their pets. The largest chunk of the overall spending went to food ($22.6 billion), followed by the veterinary care category ($15.3 billion) and then supplies/Over-the-Counter medicine ($13.7 billion). As noted by Embrace Pet Insurance, the supplies/OTC meds category remains robust, with their analysts estimating that growth in this sector outpaced the 6.7% expansion forecast by American Pet Products in 2013.
Vape Holdings & Terra Tech Were Top Cannabis Stock Gainers Last Week
ACCESSWIRE - Tue Aug 12, 8:47AM CDT
WHITEFISH, MT / August 12, 2014 / The Marijuana Index(TM) moved lower last week, as bellwethers GW Pharmaceuticals plc (NASDAQ: GWPH) and MedBox Inc. (OTC: MDBX) fell 0.8% and 14%, respectively, alongside many other smaller industry components.
Cannabis Therapy Corp. Moves to Leverage Pet Health Sector and Offers Details on New Product Lineup
Marketwire - Tue Aug 12, 8:03AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"
, a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, ultra-low THC, cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is pleased to offer additional information regarding its Canna-Pet(TM) product mix, and subsequent plans for upcoming marketing activities to support the recently announced worldwide and exclusive licensing of the entire Canna-Pet(TM) brand and animal health operation. Cannabis Therapy Expands into Animal Health Marketplace
ACCESSWIRE - Wed Aug 06, 8:35AM CDT
WHITEFISH, MT / August 6, 2014 / Consumers will spend an estimated $58.51 billion on their pets in 2014, according to the American Pet Products Association's National Pet Owners Survey, which is up 5% from the $55.72 billion spent last year. Even with the global economic crisis of 2008, the industry has managed to grow every year since 2001, as consumers are willing to spend on their pets even when they can't afford to spend on themselves.
Cannabis Therapy Corp. and Canna-Pet, LLC Enter Exclusive Licensing Agreement
Marketwire - Tue Aug 05, 8:11AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"
, a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, ultra-low THC, cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is very pleased to announce the execution of a definitive licensing agreement with Canna-Pet, LLC of Seattle, WA. Cannabis Stocks Edge Higher Last Week Led by Nuvilex & Entertopia
ACCESSWIRE - Tue Jul 22, 8:32AM CDT
WHITEFISH, MT / July 22, 2014 / The Marijuana Index(TM) moved slightly higher last week, despite a 7% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares. Medbox Inc. (OTC: MDBX), the second largest component of the index, also fell over 5% last week.
Cannabis Stocks Move Higher as Washington State Pot Sales Begin
ACCESSWIRE - Mon Jul 14, 8:30AM CDT
WHITEFISH, MT / July 14, 2014 / The Marijuana Index(TM) moved higher last week in the aggregate, despite a 13% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares and a roughly 1.5% drop in Medbox Inc. (OTC: MDBX) shares, which comprise about half of the weighted index.
Cannabis Sativa & Easton Pharmaceuticals Led Cannabis Stocks Higher Last Week
ACCESSWIRE - Tue Jul 08, 8:07AM CDT
Whitefish, MT / July 8, 2014 / The Marijuana Index(tm) was mixed last week, as index heavyweights GW Pharmaceuticals plc (NASDAQ: GWPH) and Medbox Inc. (OTC: MDBX) gave up some of their earlier gains towards the end of the week.
Cannabis Therapy Corp. Commences Research to Support Development of New, Hemp-Based, Anti-Inflammatory Products
Marketwire - Tue Jul 08, 8:03AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"
, a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is pleased to advise it is commencing exploratory laboratory research aimed at the development of cannabinoid-based products with potential application specific to inflammatory and auto-immune diseases. Marijuana Sector Positioned to Move Higher as FDA Reviews Drug's Status
ACCESSWIRE - Mon Jun 30, 8:32AM CDT
WHITEFISH, MT / June 30, 2014 / The Marijuana Index(TM) traded marginally lower last week after MedBox Inc. (OTC: MDBX) and CannaVEST Corp.'s (OTC: CANV) moves lower offset GW Pharmaceuticals plc's (NASDAQ: GWPH) modest gains.
Cannabis Therapy Corp. Views FDA Reclassification Analysis as a Potential Win for Both Industry and Consumers
Marketwire - Mon Jun 30, 8:02AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"
a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is very pleased to note recent media reports that the U.S. Food and Drug Administration ("FDA" , at the request of the Drug Enforcement Administration ("DEA" , is conducting an analysis on whether the U.S. should downgrade the classification of marijuana as a Schedule 1 drug. Cannabis Therapy Corp. Crop Management Advantage Accelerates Regional Farm Activity
Marketwire - Wed Jun 25, 8:03AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"
a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is pleased to advise that its initial crop of hemp cultivars is well underway with plants exhibiting normal healthy growth characteristics and a current height of approximately 16 inches. Cannabis Therapy Uses Hemp to Shorten Time to Market
ACCESSWIRE - Mon Jun 23, 9:14AM CDT
WHITEFISH, MT / June 23, 2014 / Medical marijuana remains very controversial despite the favorable regulatory progress made over the past couple of years. While NORML polls suggest 80% of U.S. citizens support medical marijuana legalization, the remaining 20% represent a vocal minority that continue to campaign against it. Perhaps most importantly, the U.S. federal government still considers marijuana to be a Schedule I Controlled Substance.
Cannabis Therapy Pursues IP Strategy in Cannabis Industry
ACCESSWIRE - Wed Jun 18, 8:29AM CDT
Whitefish, MT / June 18, 2014 / Cannabis Therapy Corp (OTC: CTCO) a development stage company that aims to become a leader in the research, development, and commercialization of cannabinoid-based medicinal therapies and supplements, recently announced that it has selected international law firm Nixon Peabody LLP to manage and protect its current and future intellectual property assets.
Cannabis Therapy Corp. Engages Nixon Peabody LLP for IP Protection
Marketwire - Wed Jun 18, 1:27AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"
, a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), has selected international law firm Nixon Peabody LLP to manage and protect its current and future intellectual property assets. CannabisFN Weekly: Stocks Tread Water amid Regulatory Gains
ACCESSWIRE - Tue Jun 17, 1:00PM CDT
Whitefish, MT / June 17, 2014 / The Marijuana Index(tm) traded roughly even last week, although the sector remains well below its highs achieved earlier this year.
Cannabis Therapy Corp. CEO Conducts In-Depth Video Interview on CFN
Marketwire - Thu Jun 12, 8:02AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"
a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is very pleased to advise that its CEO, Dr. Soren Mogelsvang, recently conducted an in-depth video interview regarding the Company's goals and path to sustainability which is now available for review at http://bit.ly/1lkUK5l. Cannabis Therapy Corp. Announces Close of Restructuring and Confirms Appointment of Biotech Executive as Director
Marketwire - Wed Apr 02, 8:03AM CDT
Cannabis Therapy Corp. (OTCQB: CTCO) (formerly OTCQB: FWSI) (the "Company"
is pleased to advise it has successfully concluded its previously announced corporate restructuring in connection with its entry into the business of manufacturing and marketing pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of cannabis, for the treatment of various conditions and diseases. 
